Automating Gastroenterology Home Infusion Prior Auth

Klivira simplifies **gastroenterology home infusion prior auth**, enabling GI practices to accelerate patient access to critical biologic therapies for chronic conditions like IBD.

For revenue cycle directors and prior authorization teams, managing home infusion prior authorizations in gastroenterology presents unique challenges. The high volume of IBD biologic therapies, coupled with complex payer policies and chronic re-authorization cycles, often leads to administrative burden and delays in patient care. Klivira's platform is designed to navigate these complexities.

The Unique Landscape of GI Home Infusion Prior Authorization

Home infusion therapy is a cornerstone for managing chronic gastrointestinal conditions, particularly Inflammatory Bowel Disease (IBD). Securing prior authorization for these high-cost biologic agents, such as infliximab or vedolizumab, requires precise documentation and adherence to specific payer criteria. The workflow for **gastroenterology home infusion prior auth** is further complicated by the need for ongoing re-authorizations and the nuanced interplay between medical and pharmacy benefits.

Common Biologics Requiring Home Infusion Prior Authorization in GI

Infliximab (Remicade and biosimilars) for Crohn's disease and ulcerative colitis.
Vedolizumab (Entyvio) for Crohn's disease and ulcerative colitis.
Ustekinumab (Stelara) for Crohn's disease.
Risankizumab (Skyrizi) for Crohn's disease.
Other specialty IBD drugs administered via infusion.

Navigating Documentation and Clinical Guidelines for GI Biologics

Successful prior authorization for GI home infusion biologics relies heavily on comprehensive clinical documentation. Payers often require evidence of diagnosis confirmation (endoscopic, imaging, histologic), disease severity assessment (e.g., Mayo score for UC, CDAI for Crohn's), and compliance with step therapy protocols. Klivira's logic incorporates guidelines from bodies like the ACG, AGA, and AASLD to ensure all necessary data points are captured and presented accurately, minimizing manual review and potential denials.

Mitigating Common Denial Reasons for GI Home Infusion PAs

Failure to demonstrate step therapy compliance with conventional or preferred biologic agents.
Insufficient documentation of disease severity or response to prior therapies.
Gaps in required pre-treatment screenings (e.g., TB, hepatitis).
Misclassification of treatment-naive vs. treatment-experienced status.
Payer mandates for biosimilar substitution not addressed.

Klivira's Solution for Streamlined GI Home Infusion Prior Authorization

Klivira's platform automates the complex prior authorization workflow for gastroenterology home infusion therapies. By integrating directly with EMR systems, we extract critical clinical data, apply ACG/AGA-guideline-aware step therapy logic, and intelligently route medical-vs-pharmacy benefit claims. This approach ensures accurate submission packages and facilitates periodic re-authorization for chronic IBD treatments, freeing up PA coordinators.

EMR Integration and Payer Connectivity for GI Workflows

Klivira connects seamlessly with leading EMRs via SMART on FHIR and other integration methods to pull relevant patient data, including medication history, lab results, and diagnostic reports. Our platform then communicates with payer portals and utilizes standardized transactions like X12 278 for electronic prior authorization (ePA) submissions. This comprehensive connectivity ensures that the entire **gastroenterology home infusion prior auth** process is digital, efficient, and auditable.

Frequently asked questions

How does Klivira manage the chronic re-authorization burden for IBD biologics in home infusion?

Klivira's system tracks re-authorization cycles for chronic IBD biologics, proactively alerting teams and pre-populating renewal requests with updated clinical data from the EMR. This ensures timely submissions and continuity of care for patients on home infusion therapy.

What specific EMR data points are crucial for gastroenterology home infusion PAs?

Key EMR data includes diagnosis codes, disease activity scores (e.g., Mayo, CDAI), medication history (prior therapies, dosages), lab results (e.g., TB/Hepatitis screening), and physician notes detailing treatment rationale. Klivira automates the extraction and mapping of these critical data elements.

How does Klivira handle the medical vs. pharmacy benefit split for infused biologics?

Klivira's platform intelligently routes prior authorization requests based on the administration mode of the biologic—whether it's provider-administered (medical benefit) or self-administered via home infusion (often pharmacy benefit, sometimes medical). This ensures the correct benefit channel is engaged from the outset, reducing submission errors.

Which clinical guidelines inform Klivira's GI prior authorization logic?

Klivira's logic is informed by widely accepted clinical guidelines from organizations such as the American College of Gastroenterology (ACG), American Gastroenterological Association (AGA), and American Association for the Study of Liver Diseases (AASLD). This ensures alignment with evidence-based medicine and payer medical necessity criteria.

Can Klivira assist with step therapy requirements for IBD biologics?

Yes, Klivira incorporates ACG/AGA-guideline-aware step therapy logic. The platform identifies required conventional or preferred biologic trials based on payer policies and helps document adherence, or provides the necessary clinical rationale for exceptions, streamlining compliance and reducing denials.